Ranolazine + Placebo

Phase 3Terminated

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Heart; Dysfunction Postoperative, Cardiac Surgery

Conditions

Heart; Dysfunction Postoperative, Cardiac Surgery

Trial Timeline

Sep 1, 2010 → Nov 1, 2012

NCT ID

NCT01352416

About Ranolazine + Placebo

Ranolazine + Placebo is a phase 3 stage product being developed by Gilead Sciences for Heart; Dysfunction Postoperative, Cardiac Surgery. The current trial status is terminated. This product is registered under clinical trial identifier NCT01352416. Target conditions include Heart; Dysfunction Postoperative, Cardiac Surgery.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03044964	Approved	UNKNOWN	Jan 10, 2017	Oct 1, 2017	Angina
NCT02829034	Approved	Completed	Jul 1, 2016	Jan 1, 2018	Pulmonary Hypertension
NCT02423265	Approved	Withdrawn	Jun 1, 2015	Mar 1, 2017	Myocardial Ischemia
NCT02147067	Phase 2	Completed	Sep 1, 2014	Jun 1, 2018	Microvascular Angina
NCT02156336	Approved	Terminated	May 1, 2014	Feb 8, 2017	Diabetic Peripheral Neuropathic Pain
NCT02052011	Approved	Completed	Apr 1, 2014	Nov 1, 2015	Microvascular Angina
NCT01948310	Approved	Completed	Dec 1, 2013	Oct 10, 2016	Chronic Stable Angina
NCT01887353	Phase 2	Terminated	Jun 1, 2013	Feb 1, 2014	Atrial Fibrillation
NCT01767987	Phase 2	Terminated	Nov 1, 2012	Apr 1, 2014	Acute Coronary Syndrome
NCT01590979	Pre-clinical	Terminated	Apr 1, 2012	Jun 1, 2015	Atrial Fibrillation New Onset
NCT01558830	Approved	UNKNOWN	Jan 1, 2012	Jul 1, 2013	Chronic Stable Angina
NCT01472185	Phase 3	Completed	Nov 1, 2011	Oct 1, 2013	Type 2 Diabetes Mellitus
NCT01442038	Phase 3	Completed	Oct 1, 2011	Feb 1, 2015	Coronary Artery Disease
NCT01505179	Pre-clinical	Completed	Feb 1, 2011	Jan 1, 2015	Heart Failure With Preserved Ejection Fraction
NCT01352416	Phase 3	Terminated	Sep 1, 2010	Nov 1, 2012	Heart; Dysfunction Postoperative, Cardiac Surgery
NCT01163721	Phase 2	Completed	Jun 1, 2010	Nov 1, 2010	Diabetes Mellitus, Type 2
NCT00832572	Approved	Terminated	Jan 1, 2009	Jun 1, 2009	Coronary Artery Disease
NCT00099788	Phase 3	Completed	Oct 1, 2004	Feb 1, 2007	Myocardial Ischemia

Competing Products

20 competing products in Heart; Dysfunction Postoperative, Cardiac Surgery

See all competitors

Product	Company	Stage	Hype Score
IV diuretic	Nuwellis	Pre-clinical	15
IV Loop Diuretics	Nuwellis	Pre-clinical	15
Stepped pharmacologic care	Nuwellis	Phase 3	69
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	15
TRV120027 + Normal Saline	Trevena	Phase 1	25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	44
TRV120027 + Placebo	Trevena	Phase 1/2	33
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	44
INXN-4001	Precigen	Phase 1	28
LY3461767 + Placebo	Eli Lilly	Phase 1	33
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	85
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	52
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	85
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	77
Olmesartan	Daiichi Sankyo	Phase 3	77
Carperitide + Placebo	Daiichi Sankyo	Phase 2	52
Edoxaban	Daiichi Sankyo	Pre-clinical	23
Regadenoson	Astellas Pharma	Phase 1	33
Advagraf + Prograf	Astellas Pharma	Phase 2	52
FK506E	Astellas Pharma	Phase 3	77

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved